Eli Lilly Stock: A Screaming Buy for Investors Eyeing Tremendous Growth
Thursday, 2 May 2024, 09:45
Eli Lilly Stock: A Screaming Buy
The biggest healthcare company in the world could grow much larger over the next decade. Shares of Eli Lilly and Company (NYSE: LLY) have soared nearly 35% so far in 2024 and are only a few points away from doubling over the last 12 months. The company reigns as the biggest drugmaker in the world based on market cap.
Key Points:
- Tremendous growth ahead for Mounjaro and Zepbound: Lilly's type 2 diabetes and weight loss drugs are generating strong sales, with potential for further expansion into new markets.
- Potentially better weight-loss drugs in the pipeline: The company's innovative pipeline includes promising candidates that could outperform existing products.
- Many more promising candidates: Lilly's diverse portfolio of products, including treatments for Alzheimer's and Crohn's disease, positions it for sustained growth.
Despite concerns about valuation, Eli Lilly stock offers significant growth opportunities and remains a compelling choice for investors seeking long-term returns.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.